Emergent BioSolutions Inc
EBS
Detailliertes Diagramm anzeigen
7.940USD
+0.150+1.93%
Handelsschluss 09/18, 16:00（ET）Kurse um 15 Minuten verzögert
426.38MMarktkapitalisierung
3.06KGV TTM
Intraday
1m
30m
1h
D
W
M
D
Heute
+1.93%
5 Tage
-3.52%
1 Monat
-12.46%
6 Monate
+39.54%
Seit Jahresbeginn
-16.95%
1 Jahr
+15.07%
Detailliertes Diagramm anzeigen
TradingKey Aktien-Score
Währung: USD Aktualisiert: 2025-09-18Wichtige Einblicke
Die Fundamentaldaten des Unternehmens sind relativ gesund. Seine Bewertung wird als unterbewertet angesehen,und die institutionelle Anerkennung ist sehr hoch. In den letzten 30 Tagen haben mehrere Analysten die Aktie mit einer Halten bewertet. Das Unternehmen zeigt eine starke Leistung am Aktienmarkt, mit soliden Fundamentaldaten und technischen Kennzahlen, die den Aufwärtstrend unterstützen. Der Aktienkurs bewegt sich seitwärts zwischen den Unterstützungs- und Widerstandsniveaus, was ihn für schwankungsorientiertes Trading geeignet macht.
Aktienbewertung
Widerstand & Unterstützung
Keine Daten
Radar Chart
Aktueller Preis
Vorher
Analysten-Ziel
Basierend auf insgesamt
3
Analysten
Halten
Aktuelles Rating
13.500
Kursziel
+73.30%
Aufwärtspotenzial
Hinweis: Analystenbewertungen und Kursziele werden von LSEG ausschließlich zu Informationszwecken bereitgestellt und stellen keine Anlageberatung dar.
Unternehmens-Highlights
HöhepunkteRisiko
Emergent BioSolutions, Inc. is a life sciences company. It is focused on providing preparedness and response solutions addressing accidental, deliberate and naturally occurring public health threats. Its solutions include a product portfolio, a product development portfolio, and a Bioservices portfolio. Its segments include Commercial Products, MCM Products, and Services Segment. Commercial Products segment include NARCAN (naloxone HCl). MCM Products segment consists of its Anthrax - MCM, Smallpox - MCM and Other Products. Services segment consisting of its Bioservices offerings. NARCAN (naloxone HCl) Nasal Spray, an intranasal formulation of naloxone is developed for the emergency treatment of known or suspected opioid overdose as manifested by respiratory and/or central nervous system depression. Its portfolio of Bioservices consists of three but interrelated service pillars, such as development services (process and analytical development) and drug substance manufacturing.
valuation_overestimated
valuation_overestimated_desc%!(EXTRA string=PE, string=2.98)
institutional_decreasing_position
institutional_decreasing_position_desc%!(EXTRA string=39.60M, string=17.23%)
institutional_hold%!(EXTRA string=The Vanguard)
institutional_hold_desc%!(EXTRA string=The Vanguard, string=3.58M)
Nachrichten
Bald gibt es mehr Neuigkeiten, bleiben Sie dran...
Finanzindikatoren
EPS
Keine Daten
Gesamteinnahmen
Keine Daten
Unternehmen
Emergent BioSolutions, Inc. is a life sciences company. It is focused on providing preparedness and response solutions addressing accidental, deliberate and naturally occurring public health threats. Its solutions include a product portfolio, a product development portfolio, and a Bioservices portfolio. Its segments include Commercial Products, MCM Products, and Services Segment. Commercial Products segment include NARCAN (naloxone HCl). MCM Products segment consists of its Anthrax - MCM, Smallpox - MCM and Other Products. Services segment consisting of its Bioservices offerings. NARCAN (naloxone HCl) Nasal Spray, an intranasal formulation of naloxone is developed for the emergency treatment of known or suspected opioid overdose as manifested by respiratory and/or central nervous system depression. Its portfolio of Bioservices consists of three but interrelated service pillars, such as development services (process and analytical development) and drug substance manufacturing.
BörsenkürzelEBS
UnternehmenEmergent BioSolutions Inc
CEOMr. Joseph C. (Joe) Papa
Websitehttps://emergentbiosolutions.com/
Verwandte Finanzinstrumente
+0.37%
-1.72%
+0.53%
-0.80%
-0.15%
+6.27%
+0.48%
+0.41%
+1.21%
+0.42%
+1.51%
-0.01%
-1.19%
-0.30%
-0.15%
-1.70%
-0.03%
+0.12%
+2.26%
+0.10%
